Science

Gilberto Lopes

Mar 1, 2025, 12:41

Gilberto Lopes: ctDNA decrease and clearance are associated with PFS and OS in lung cancer

Gilberto Lopes, Chief of the medical oncology division and professor of clinical medicine at the Miller School of Medicine, shared an article by Luís F Leite da Silva, et al. on X:

“Our meta-analysis aggregates data from more the 30 studies comprising 3000+ patients, showing that ctDNA decrease and clearance are strongly associated with PFS and OS in lung cancer.

Results hold true for targeted treatments and immunotherapy!

Time is ripe to include as outcome in prospective studies so we can incorporate in decision making and drug approval process – FDA Oncology.”

Plasma ctDNA kinetics as a predictor of systemic therapy response for advanced non-small cell lung cancer: a systematic review and meta-analysis.

Authors: Luís F Leite da Silva, et al.

Gilberto Lopes: ctDNA decrease and clearance are associated with PFS and OS in lung cancer

cancer ctDNA FDA Oncology fight against cancer Gilberto Lopes Global fight against cancer immunotherapy Luís F Leite da Silva Lung cancer MedOnc Miller School of Medicine non small cell lung cancer NSCLC OncoDaily Oncology OS PFS

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research